Let's not forget the downgrade to neutral on Intermune days before Roche takeout last month.
Sentiment: Strong Buy
tks for that little chunk of history. I have held GILD for 3 yrs, and saw all the idiots make stupid upgrades/downgrades, move PTs, make really low rev fcsts, etc. Many times I was tempted to sell, but I held on.
I doubt MDVN will be a 5 bagger from here in 5 yrs, but i don't doubt it will be a 5 bagger from the 55 it saw back in May or so, in 3 yrs from that time, ie, I expect 200+ in 2 yrs or less.
GS removes it from their Americas Buy List, cuts to neutral from buy, and raises their PT from 90 to 110.
More wall st gibberish, what it really means, imo, is that GS wants to buy more at lower prices.
GS likely has the worst biotech analysts. A couple months ago they downgraded Gilead and put a $68 price target on it. You can see how well that one worked out
bominreal I have been long a stock that is up 1200% that you have repeatedly blasted. During this same time you have posted many times in favor of a stock that's down 95%. You should start a new career as a comedian, stock picking is not your thing.
anyhow mdvn still holding my shorts
we all play both side..
you have no reason to bashing dndn at 1 area.
you should focaus on mdvn.
dont act like a xxxxxc
I made much more than I lost on my Dendreon and even made money today on Dendreon. Much more to come my foreign friend. Go look at my posts from 5 yrs ago grasshopper and you will learn
Well, the world is littered with corpses of dead patients deprived of life saving treatments such as Provenge, Neuvenge...
agree all these posts not going to move price.
dndn or mdvn..
dndn boards has many more nuts head..
If you have time to correct grammar you must live a shallow existence. Now back to licking your DNDN losses for you.
In this case it is THEN not than and what makes you think I would waste my time looking for how long a puppet like you has been posting?
In my opinion the article includes erroneous data, as follows : I cite:
" Canaccord Genuity upgraded its rating on Medivation to Buy from Hold, as well as more than doubling its price target to $132.00 from the previous target of $60.00.
The earnings per share estimate for 2014 has been revised to $1.88 from $3.03. The estimate for 2015 has been revised to $0.39 from $1.93 per share."
If they lowered so much their estimates for the earnings, why they doubled the the price target?
Down today but when the profits start to show this is going up in a big way, every dip is a buy with this company regardless of Cramer.
Sentiment: Strong Buy
You paranoid DNDN'ers need to get over your fears of institutions hiring people to post. If you really care you can look back three years ago and see I was posting than. Why would someone pay for me or anyone yo post? Do you really believe these posts move the price of a stock? If so you should find yourself a nice "safe" bond fund.